局限期小细胞肺癌胸部放疗方案:系统综述与网状Meta分析
该系统综述与网状Meta分析纳入8项RCT共2363例局限期小细胞肺癌患者,比较不同胸部放疗方案的疗效与安全性。以45 Gy/30f BID为对照,hHyper-RT(54 Gy/30f BID和60 Gy/40f BID)改善OS,hHyper-RT(54 Gy/30f BID)和Hypo-RT(65 Gy/26f QD)延长PFS,Conv-RT(45 Gy/25f QD)降低食管炎风险。
要点
- hHyper-RT(54 Gy/30f BID和60 Gy/40f BID)较45 Gy/30f BID改善OS。
- hHyper-RT(54 Gy/30f BID)和Hypo-RT(65 Gy/26f QD)较45 Gy/30f BID延长PFS。
- Conv-RT(45 Gy/25f QD)较45 Gy/30f BID降低食管炎及3-5级食管炎风险。
核心结论
- 与45 Gy/30f BID相比,hHyper-RT(54 Gy/30f BID和60 Gy/40f BID)改善OS,hHyper-RT(54 Gy/30f BID)和Hypo-RT(65 Gy/26f QD)延长PFS,且毒性可接受。
研究设计与样本
- 系统综述与网状Meta分析,检索PubMed、Cochrane Library、Web of Science和EMBASE的RCT,最终纳入8项RCT共2363例患者。
主要发现
- hHyper-RT(54 Gy/30f BID)较45 Gy/30f BID改善OS(HR=0.55,95%CI:0.37-0.82)。
- hHyper-RT(60 Gy/40f BID)较45 Gy/30f BID改善OS(HR=0.69,95%CI:0.48-0.99)。
- hHyper-RT(54 Gy/30f BID)较45 Gy/30f BID延长PFS(HR=0.70,95%CI:0.49-0.99)。
- Hypo-RT(65 Gy/26f QD)较45 Gy/30f BID延长PFS(HR=0.78,95%CI:0.62-0.98)。
- Conv-RT(45 Gy/25f QD)较45 Gy/30f BID降低食管炎风险(RR=0.70,95%CI:0.58-0.85)和3-5级食管炎风险(RR=0.50,95%CI:0.35-0.72)。
关键数值与推荐
- 对照方案为45 Gy/30f BID。
- 实验组分为hHyper-RT(54 Gy/30f BID、60 Gy/40f BID)、Hypo-RT(42 Gy/15f QD、65 Gy/26f QD)和Conv-RT(45 Gy/25f QD、66 Gy/33f QD、70 Gy/35f QD)。
- Conv-RT的OS和PFS与45 Gy/30f BID相当。
- 45 Gy/30f、hHyper-RT和Hypo-RT之间AE发生情况相当。
- 各研究组间ORR、肺炎及3-5级肺炎无显著差异。
临床怎么用
- hHyper-RT(54 Gy/30f BID和60 Gy/40f BID)较45 Gy/30f BID改善OS,hHyper-RT(54 Gy/30f BID)和Hypo-RT(65 Gy/26f QD)延长PFS,毒性可接受。
- Conv-RT(45 Gy/25f QD)较45 Gy/30f BID降低食管炎及3-5级食管炎风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, the accepted standard management of limited-stage small cell lung cancer (LS-SCLC) is concurrent chemoradiotherapy; however, the thoracic radiotherapy regimen remains controversial. Therefore, this meta-analysis aims to compare efficacy and safety of different thoracic radiotherapy regimens. METHODS: Relevant randomized controlled trials (RCTs) were sourced in PubMed, Cochrane Library, Web of Science, and EMBASE to assess antitumor effects (overall survival, OS; progression-free survival, PFS; overall response rate, ORR) and toxicity (adverse effects, AEs). RESULTS: Of the 2225 screened articles, 8 RCTs (involving 2363 patients) were included. The control arm was defined as 45 Gy/30f BID. The experimental arms were categorized into three groups: high-dose hyper-fractionation (hHyper-RT: 54 Gy/30f BID, 60 Gy/40f BID), hypo-fractionation (Hypo-RT: 42 Gy/15f QD, 65 Gy/26f QD), and conventional fractionation (Conv-RT: 45 Gy/25f QD, 66 Gy/33f QD, 70 Gy/35f QD). Compared with 45 Gy/30f BID, hHyper-RT (54 Gy/30f BID and 60 Gy/40f BID) showed improved OS (HR = 0.55, 95 % CI: 0.37---0.82; HR = 0.69, 95 % CI: 0.48---0.99), hHyper-RT (54 Gy/30f BID) and Hypo-RT (65 Gy/26f QD) improved PFS (HR = 0.70, 95 % CI: 0.49---0.99; HR = 0.78, 95 % CI: 0.62---0.98), whereas OS and PFS with Conv-RT was comparable to that of 45 Gy/30f BID. AE development was comparable among 45 Gy/30f, hHyper-RT, and Hypo-RT, whereas Conv-RT (45 Gy/25f QD) reduces the risk of esophagitis and grade 3-5 esophagitis (RR = 0.70, 95 % CI: 0.58-0.85; RR = 0.50, 95 % CI: 0.35-0.72). No significant difference was found for ORR, pneumonitis or grade 3-5 pneumonitis between the study arms. CONCLUSIONS: Compared with 45 Gy/30f BID, hHyper-RT (54 Gy/30f BID and 60 Gy/40f BID) improved OS, while hHyper-RT (54 Gy/30f BID) and Hypo-RT (65 Gy/26f QD) prolonged PFS in LS-SCLC patients, with accepted toxicity.
引用
- Zhong X, Liu Y, Ji Y, et al. Thoracic radiotherapy schedules in limited-stage small cell lung cancer: A systematic review and network meta-analysis. Radiother Oncol. 2025. PMID: 40209857. doi:10.1016/j.radonc.2025.110888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。